https://www.preprints.org/manuscript/202005.0486/v1
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
How to cite: Guérin, V.; Lévy, P.; Thomas, J.; Lardenois, T.; Lacrosse, P.; Sarrazin, E.; Regensberg de Andreis, N.; Wonner, M. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. Preprints 2020, 2020050486 (doi: 10.20944/preprints202005.0486.v1). Guérin, V.; Lévy, P.; Thomas, J.; Lardenois, T.; Lacrosse, P.; Sarrazin, E.; Regensberg de Andreis, N.; Wonner, M. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. Preprints 2020, 2020050486 (doi: 10.20944/preprints202005.0486.v1).
Abstract
- The mean (SD) times to achieve clinical recovery were respectively 25.8 days (11.1), 12.9 days (13.4) and 9.2 days (9.3), showing a statistically significant difference between NST and AZM alone (p<0.0001) or AZM+HCQ (p<0.0001).
To improve the evidence level, a case-control analysis was performed on a sample of 57 patients (19/group) matched for age, sex and BMI. The statistical difference between NST and AZM was confirmed (p=0.0149) as well as the difference with AZM+HCQ (p=0.0002). No cardiac toxicity was recorded in any patient. No statistical difference was shown between AZM and AZM+HCQ groups, although the dual therapy tended to be more effective in patients over 50 years, based on an analysis using the cox model.
In conclusion, AZM and AZM+HCQ favourably impacted the course of the disease. We need trials, ideally prospective/double blind, to show if a statistical difference can be evidenced with a broader group, and clarify the indications of each treatment depending on initial clinical presentation.
____________________
For more: https://madisonarealymesupportgroup.com/2020/06/01/rebuttal-on-huge-hcq-study-in-lancet/
https://madisonarealymesupportgroup.com/2020/03/20/herbal-treatment-for-covid-19-addendum-buhner/